European Heart Journal Advance Access originally published online on July 26, 2007
European Heart Journal 2007 28(19):2338-2345; doi:10.1093/eurheartj/ehm293
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Decennial follow-up in patients with recurrent tachycardia originating from the right ventricular outflow tract: electrophysiologic characteristics and response to treatment
1 Department of Cardiology, University Heart Center, Martinistrasse 52, 20246 Hamburg, Germany
2 Department of Cardiology, Asklepios Hospital, St Georg, Hamburg, Germany
Received 21 November 2006; revised 22 April 2007; accepted 14 June 2007; online publish-ahead-of-print 26 July 2007.
* Corresponding author. Tel: +49 40428034120; fax: +49 40428034125. E-mail address: ventura{at}uke.uni-hamburg.de
Aims: In the setting of right ventricular outflow tract-tachycardia (RVOT-T), data about long-term follow-up (FU) with respect to the therapeutic strategies are missing. All patients (pts) referred to our institution during the last 20 years for the treatment of RVOT-T were studied in a retrospective analysis to assess mortality and efficacy of treatment.
Methods and results: One hundred and thirty-three patients (77 female; 39 ± 13 years) with sustained RVOT-T were included in this study. At the time of first presentation, diagnosis of RVOT-T was made by complete invasive and non-invasive diagnostic assessment, including electrophysiology study and two-dimensional echocardiography. After 135 ± 68 months (median 136, range 29–248), patients were invited to undergo clinical assessment. Of the 133 pts, 127 (95%) survived and six (5%) died from non-cardiac disease. Anti-arrhythmic (AA) drugs were given to 62 of the 133 pts (47%); of them 32 (52%) had recurrences during follow-up. The mean time to recurrence was 10.02 years (95% CI 7.46–12.59). The other 71 study patients (53%) underwent catheter ablation. The procedure was successful in 58 pts (82%). During follow-up, 30 (52%) of the 58 successfully treated patients had recurrences of RVOT-T. The mean time to recurrence was 6.28 years (95% CI 4.96–7.6). RVOT-T recurrences were similar in morphology to those treated previously in 33% and different in 67% of cases.
Conclusions: Long-term follow-up in patients with RVOT-T is favourable. Catheter ablation is effective in this setting. However, late recurrences with similar or different morphology may arise in half of the patients after initially successful treatment. AA drug therapy is a valid initial therapeutic option, since it is effective in about half of the patients.
Key Words: Idiopathic ventricular tachycardia • Drugs • Catheter ablation